Key result
FIRM-guided ablation was not associated with a significant difference in 1-year freedom from atrial fibrillation compared to conventional ablation (65% vs 50%; P=0.18).
Why the study?
The role of FIRM-guided ablation for AF remains unclear, as previous studies have been limited by patient population heterogeneity and a focus on AF termination as an endpoint.
Does FIRM-guided ablation improve AF termination, inducibility, and freedom from AF compared to conventional ablation in patients with persistent AF undergoing first-time ablation?
Cohort (n=85)
Does FIRM-guided ablation improve AF termination, inducibility, and freedom from AF compared to conventional ablation in patients with persistent AF undergoing first-time ablation?
Absolute Event Rate: 65% vs 50%
p-value: p=0.18
FIRM-guided ablation does not significantly improve AF termination, inducibility, or long-term freedom from AF compared to conventional ablation in patients with persistent AF.
No benefit with FIRM-guided ablation in persistent AF; leaves open need for randomized confirmation.
INTRODUCTION: The role of focal impulse and rotor modulation (FIRM)-guided ablation for the treatment of atrial fibrillation (AF) remains unclear. Previous studies on the FIRM-guided ablation outcomes have been limited by a focus on AF termination as an endpoint and by patient population heterogeneity. We sought to determine differences in rates of AF termination, inducibility, and recurrence in patients with persistent AF undergoing first-time ablation with a FIRM-guided approach compared with patients undergoing conventional ablation. METHODS AND RESULTS: Eight-five consecutive patients (38 FIRM, 47 conventional) with persistent AF undergoing first-time ablation were retrospectively analyzed. There were no significant differences in the rates of AF termination in the FIRM group compared to the conventional group (26% vs 15%; P = .15). Rates of inducible AF after ablation were 37% in the FIRM group and 30% in the conventional group (P = .32). Over a median follow-up of 2.4 years, the rates of freedom from AF were similar between the FIRM and conventional groups (1-year freedom from AF 65% vs 50%, respectively; P = .18). Procedural termination of AF with either FIRM ablation or conventional ablation was not associated with any significant reduction in AF recurrence. CONCLUSION: A FIRM-guided approach was not associated with a significant difference in freedom from AF when compared to conventional ablation. Termination of AF with ablation was not associated with increased freedom from AF. While AF termination using substrate-based ablation may have mechanistic implications for understanding AF rotor physiology, its impact on clinical outcomes remains unclear.
No takes yet. Share an insight, caveat, or question.
Kirzner et al. (2019) conducted a cohort in persistent atrial fibrillation (n=85). FIRM-guided ablation vs. conventional ablation was evaluated on 1-year freedom from AF (p=0.18). FIRM-guided ablation was not associated with a significant difference in 1-year freedom from atrial fibrillation compared to conventional ablation (65% vs 50%; P=0.18).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: